Rocket Pharmaceuticals
RCKT
149 hedge funds and large institutions have $1.04B invested in Rocket Pharmaceuticals in 2022 Q1 according to their latest regulatory filings, with 22 funds opening new positions, 57 increasing their positions, 46 reducing their positions, and 21 closing their positions.
24% more repeat investments, than reductions
Existing positions increased: 57 | Existing positions reduced: 46
1.68% more ownership
Funds ownership: 98.13% → 99.81% (+1.7%)
5% more first-time investments, than exits
New positions opened: 22 | Existing positions closed: 21
1% more funds holding
Funds holding: 148 → 149 (+1)
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
25% less capital invested
Capital invested by funds: $1.38B → $1.04B (-$343M)
74% less call options, than puts
Call options by funds: $65K | Put options by funds: $250K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
+$15.3M |
| 2 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
+$13.5M |
| 3 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$7.39M |
| 4 |
State Street
Boston,
Massachusetts
|
+$7.09M |
| 5 |
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Toronto,
Ontario, Canada
|
+$6.77M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
Tang Capital Management
San Diego,
California
|
-$21.9M |
| 2 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
-$18M |
| 3 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$10.9M |
| 4 |
N
Natixis
Paris,
France
|
-$4.92M |
| 5 |
PA
Perceptive Advisors
New York
|
-$4.86M |
RCKT Hedge Fund Activity: Q1 2022 in Review
149 of the 6,360 institutional investors tracked by Wall St. Rank reported a position in Rocket Pharmaceuticals (RCKT) for Q1 2022, worth a combined $1.04B — down 25% from $1.38B a quarter earlier.
Buyers outnumbered sellers: 22 funds opened new RCKT positions and 21 closed out — a net gain of 1 holder — while 57 added to existing stakes and 46 trimmed.
The largest buyer was Goldman Sachs, adding an estimated $15.3M. The largest seller was Tang Capital Management, cutting an estimated $21.9M.
- 149 institutional investors held Rocket Pharmaceuticals (RCKT) as of Q1 2022, up from 148 in Q4 2021.
- Funds reported $1.04B of Rocket Pharmaceuticals stock for Q1 2022, down 25% quarter-over-quarter.
- 22 funds opened new Rocket Pharmaceuticals positions in Q1 2022 and 21 closed out, a net change of +1 holder.
- The largest Rocket Pharmaceuticals buyer in Q1 2022 was Goldman Sachs, an estimated $15.3M added.
- The largest Rocket Pharmaceuticals seller in Q1 2022 was Tang Capital Management, an estimated $21.9M sold.
Based on aggregated 13F filings for Q1 2022.